APOGEE THERAPEUTICS I

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

18 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results

12 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

04 Nov 2024 06:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases

24 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

16 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit

12 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer

09 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

19 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results

12 Aug 2024 05:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

28 May 2024 06:30:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

23 May 2024 06:30:00 By Nasdaq GlobeNewswire

Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases

15 May 2024 15:01:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results

13 May 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

25 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million

12 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering

07 Mar 2024 17:49:51 By Nasdaq GlobeNewswire

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

05 Mar 2024 15:23:09 By Nasdaq GlobeNewswire

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

05 Mar 2024 05:10:00 By Nasdaq GlobeNewswire

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days

05 Mar 2024 05:00:00 By Nasdaq GlobeNewswire